

Rapid Reaction: CAPE COD

Special Guest: Carolyn Magee Bell, PharmD, BCCCP, FCCM

CAPE COD Trial

Dequin PF, Meziani F, Quenot JP, et al. Hydrocortisone in Severe Community-Acquired Pneumonia. *N Eng J Med*. 2023 Mar 21. doi: 10.1056/NEJMoa2215145. Online ahead of print. <https://pubmed.ncbi.nlm.nih.gov/36942789/>

Guidelines

ERS/ESICM/ESCMID/ALAT Severe Community-Acquired Pneumonia Guidelines
<https://pubmed.ncbi.nlm.nih.gov/37012080/>

ATS/IDSA Community-Acquired Pneumonia Guidelines
<https://pubmed.ncbi.nlm.nih.gov/31573350/>

Articles Referenced

Meduri GU, Shih MC, Bridges L, et al. Low-dose methylprednisolone treatment in critically ill patients with severe community-acquired pneumonia. *Intensive Care Med*. 2022; 48(8): 1009-1023. <https://pubmed.ncbi.nlm.nih.gov/35723686/>

Confalonieri M, Urbino R, Potena A, et al. Hydrocortisone infusion for severe community acquired pneumonia: a preliminary randomized study. *Am J Respir Crit Care Med*. 2005; 171(3): 242-248. <https://pubmed.ncbi.nlm.nih.gov/15557131/>

Blum CA, Nigro N, Briel M, et al. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. *Lancet*. 2015; 385(9977): 1511-1518. <https://pubmed.ncbi.nlm.nih.gov/25608756/>

Wittermans E, Vestjens SMT, Spoorenberg SMC, et al. Adjunctive treatment with oral dexamethasone in non-ICU patients hospitalised with community-acquired pneumonia: a randomised clinical trial. *Eur Respir J*. 2021; 58(2): 2002535. <https://pubmed.ncbi.nlm.nih.gov/33446608/>



Dequin PF, Heming N, Meziani F, et al. Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial. *JAMA*. 2020; 324(13): 1298-1306. <https://pubmed.ncbi.nlm.nih.gov/32876689/>